Ovid Therapeutics Announces Pricing of $60 Million Private Placement
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: GlobeNewswire
Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasmsFinancing led by Point72 with participation from additional investors including Adage Capital Management, ADAR1 Capital Management, Affinity Asset Advisors, LLC, Ally Bridge Group, Balyasny Asset Management, Coastlands Capital, Eventide Asset Management, Janus Henderson Investors and RA Capital Management NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of $60.0 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about March 19, 2026, subject to
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics (OVID) had its price target raised by Wedbush from $5.00 to $7.00. They now have an "outperform" rating on the stock.MarketBeat
- Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding [Seeking Alpha]Seeking Alpha
- Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Here's Why Ovid Therapeutics Stock Popped Higher Today [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
OVID
Earnings
- 3/18/26 - Beat
OVID
Sec Filings
- 3/25/26 - Form 4
- 3/18/26 - Form S-8
- 3/18/26 - Form 10-K
- OVID's page on the SEC website